Get in Touch
For millions living with Parkinson’s, every day is a negotiation between symptoms and side effects. Newronika’s αDBS listens to the brain and responds in real time, so patients can simply live.
Conventional DBS delivers a fixed, unchanging signal regardless of how you feel hour to hour, whether you’ve taken medication, or how active you are. The brain changes constantly. Until now, therapy couldn’t.
Newronika’s αDBS is designed to monitor brain signals minute by minute and adjust stimulation automatically — keeping patients in their therapeutic window, reducing side effects, and restoring the quality of life that Parkinson’s takes away.
Every component of αDBS is designed to work together — from sensing hardware to cloud intelligence.
αDBS is an adaptive DBS platform that senses, analyzes, adapts, and learns from brain signals continuously. Newronika combines a patented proportional control algorithm with cloud-based data intelligence — creating therapy that becomes more precise over time.
Results from our first-of-its-kind clinical trial* — a randomized, double-blind crossover study comparing adaptive DBS directly against conventional DBS as an active comparator. Pilot study, N=19, Parkinson’s Disease.
*Results pending publication
Partner with Newronika to bring the next generation of adaptive brain therapy to patients who need it most.
Whether you’re a clinician, researcher, investor, or partner — we’d love to hear from you.
